Amgen stock: Piper Sandler keeps Buy rating at USD 457.00 target

Published on 10/23/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue consensus is USD 10.07 billion for November 3, 2026. Amgen stock costs EUR 393.55 on October 23, 2026 at 4:33 p.m. CEST.

Analyst target and reporting date

Piper Sandler reiterated a Buy rating and set a USD 457.00 target on October 20, 2026.
Amgen is scheduled to report third-quarter results on November 3, 2026.
Amgen stock costs EUR 393.55 at Lang & Schwarz on October 23, 2026 at 4:33 p.m. CEST.

Isometrische 3D-Illustration einer biopharmazeutischen Wertschöpfungskette von Labor bis Vertrieb mit Bioreaktoren — Amgen Inc. (ISIN US0311621009) dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette von Labor bis Versand, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) has a fresh analyst marker: Piper Sandler analyst David Amsellem reiterated a Buy rating and set a USD 457.00 price target on October 20, 2026, according to Markets Insider. At Lang & Schwarz, the stock was trading at EUR 393.55 on October 23, 2026 at 4:33 p.m. CEST.

November brings the next test

Amgen is scheduled to report third-quarter results on November 3, 2026 after the market close, with a conference call at 4:30 p.m. ET, according to MarketBeat. Consensus calls for USD 10.07 billion in revenue and USD 5.78 in earnings per share, compared with USD 9.56 billion and USD 5.64 in the year-earlier quarter.

Revenue growth meets margin pressure

Amgen's second-quarter revenue reached USD 10.05 billion for the period ended June 30, 2026, while net profit was USD 2.38 billion, compared with USD 9.17 billion and USD 1.43 billion a year earlier, according to Markets Insider. The standardized quarterly figures put diluted GAAP earnings per share at USD 4.37 for the same period. Adjusted earnings per share were USD 6.29, above the USD 5.62 consensus, according to Yahoo Finance.

Two dates shape the calendar

Amgen's investor-relations calendar lists the European Society of Medical Oncology Congress for October 24, 2026 and the third-quarter earnings conference call for November 3, 2026. The company also said on October 20, 2026 that it would present at the oncology congress, while a Tezspire release on the same date reported histologic remission and symptom improvement in eosinophilic esophagitis, according to Amgen.

What the target says

The USD 457.00 target is 3.70 percent above Amgen's USD 440.65 primary-exchange quote at 10:40 a.m. ET on October 23, 2026. The comparison uses the Nasdaq quote in US dollars, while the Lang & Schwarz price remains the euro measure for German investors. Amgen's market capitalization was USD 238.3 billion, its price-to-earnings ratio was 27.41, and its 52-week range was USD 288.00 to USD 450.98 as of October 23, 2026.

Stock position and next report

Amgen's current price sits below the USD 457.00 Piper Sandler target and below its USD 450.98 52-week high. The next earnings release will test whether the company's revenue trajectory can support the valuation investors are applying to its pipeline and established medicines.

Amgen stock price in euros

Amgen was trading at EUR 393.55 at Lang & Schwarz on October 23, 2026 at 4:33 p.m. CEST. The latest Nasdaq quote was USD 440.65 on October 23, 2026 at 10:40 a.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.